New Pharmaceuticals research report from Current Partnering is now available from Fast Market Research

Boston, MA -- (SBWire) -- 02/09/2015 --The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in vaccine and adjuvant partnering deals
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers
Average deal terms for vaccines

The report provides a detailed understanding and analysis of how and why companies enter vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

View Full Report Details and Table of Contents

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 1,000 links to online copies of actual vaccine deals along with contract documents where available as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of vaccine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in vaccine dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading vaccine deals since 2009. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of vaccine deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top big biotech companies with a brief summary followed by a comprehensive listing of vaccine deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of vaccine partnering deals signed and announced since January 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of vaccine partnering deals signed and announced since January 2009. The chapter is organized by specific vaccine and adjuvant technology type. Where contract available, the deal links via Weblink to an online version of the deal record providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in vaccine partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of vaccine technologies and products.

In addition, a comprehensive appendix is provided organized by vaccine partnering company A-Z, stage of development, theray area and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 800-844-8156

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Cancer Vaccine Partnering Terms and Agreements
- Infectious Vaccines Partnering Terms and Agreements
- Oncology Partnering Terms and Agreements
- Antibiotics Partnering Terms and Agreements
- Biomarker Partnering Terms and Agreements